To the full analysis
Huadong Medicine stock: growth
000963.SZHuadong Medicine reported $6.54B in revenue for fiscal 2025, up 4.1% on the prior year, up 5.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.4%
per year from 2006 to 2025, per share 12.1%
Earnings (Annual rate)
20.6%
per year from 2006 to 2025, per share 19.2%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.3% | 7.2% | 13.4% |
| Revenue per share | 5.3% | 6.0% | 12.1% |
| Earnings | 3.9% | 12.0% | 20.6% |
| Earnings per share | 3.9% | 10.8% | 19.2% |
| Free cash flow | 6.6% | 25.5% | no data |
| Free cash flow per share | 6.6% | 24.1% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $595.1M | $14.48M | −$3.92M |
| 2007 | $727.84M | $25.97M | $35.02M |
| 2008 | $902.26M | $25.29M | $38.46M |
| 2009 | $1.17B | $56.75M | $65.79M |
| 2010 | $1.35B | $47.58M | −$29.82M |
| 2011 | $1.67B | $57.21M | −$31.21M |
| 2012 | $2.19B | $70.47M | $57.85M |
| 2013 | $2.51B | $86.23M | $21.17M |
| 2014 | $2.84B | $113.47M | $62.38M |
| 2015 | $3.26B | $164.5M | $41.32M |
| 2016 | $3.81B | $216.94M | $131.96M |
| 2017 | $4.17B | $266.86M | $177.32M |
| 2018 | $4.6B | $340M | $174.41M |
| 2019 | $5.32B | $421.87M | $97.21M |
| 2020 | $5.05B | $422.88M | $290.7M |
| 2021 | $5.18B | $345.16M | $352.52M |
| 2022 | $5.66B | $374.79M | $178.25M |
| 2023 | $6.09B | $425.73M | $348.31M |
| 2024 | $6.28B | $526.69M | $303.09M |
| 2025 | $6.54B | $512.03M | $400.58M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.